according to the Globally Harmonized System



### Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	28.09.2024	68823-00030	Date of first issue: 27.02.2015

#### **1. PRODUCT AND COMPANY IDENTIFICATION**

Product name	:	Imipenem / Cilastatin / Relebactam Formulation				
Manufacturer or supplier's details						
Company	:	MSD				
Address	:	Briahnager - Off Pune Nagar Road Wagholi - Pune - India 412 207				
Telephone	:	+1-908-740-4000				
Emergency telephone number	:	+1-908-423-6000				
E-mail address	:	EHSDATASTEWARD@msd.com				
Recommended use of the chemical and restrictions on use						
Recommended use Restrictions on use	:	Pharmaceutical Not applicable				

#### 2. HAZARDS IDENTIFICATION

#### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

#### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

#### **GHS Classification**

Serious eye damage/eye irri- tation	:	Category 2A
Respiratory sensitisation	:	Category 1
Reproductive toxicity	:	Category 2
Specific target organ toxicity - repeated exposure	:	Category 2 (Kidney)
Short-term (acute) aquatic hazard	:	Category 1
Long-term (chronic) aquatic hazard	:	Category 1

#### GHS label elements

according to the Globally Harmonized System



### Imipenem / Cilastatin / Relebactam Formulation

Version 6.0	Revision Date: 28.09.2024	SDS Number: 68823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015
	rd pictograms Il word	: Danger	
Ũ	rd statements	: H319 Causes H334 May ca difficulties if ir H361d Suspe H373 May ca longed or rep	e serious eye irritation. use allergy or asthma symptoms or breathing haled. used of damaging the unborn child. use damage to organs (Kidney) through pro- eated exposure. kic to aquatic life with long lasting effects.
Preca	utionary statements	P233 Keep co P260 Do not I P264+P265 V touch eyes. P271 Use onI P273 Avoid re P280 Wear pot tion/ face prot	Vash hands thoroughly after handling. Do not y outdoors or with adequate ventilation. elease to the environment. rotective gloves/ protective clothing/ eye protec-
		keep comforta P305 + P351 for several mi easy to do. C P318 IF expo P337 + P317 P342 + P316	IF INHALED: Remove person to fresh air and able for breathing. + P338 IF IN EYES: Rinse cautiously with water nutes. Remove contact lenses, if present and ontinue rinsing. sed or concerned, get medical advice. If eye irritation persists: Get medical help. If experiencing respiratory symptoms: Get emer- al help immediately. spillage.
		<b>Storage:</b> P403 Store in P405 Store lo <b>Disposal:</b>	a well-ventilated place. cked up. e of contents/ container to an approved waste

#### Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

according to the Globally Harmonized System



# Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	28.09.2024	68823-00030	Date of first issue: 27.02.2015

Substance / Mixture

: Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cilastatin	81129-83-1	>= 30 - < 50
Imipenem	74431-23-5	>= 30 - < 50
Relebactam	1174020-13-3	>= 10 - < 20

#### 4. FIRST AID MEASURES

If inhaled:If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.In case of skin contact:In case of contact, immediately flush skin with s of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.In case of eye contact:In case of contact, immediately flush eyes with for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.If swallowed:If swallowed, DO NOT induce vomiting. Get medical attention. Rines mouth thoroughly with water.Most important symptoms and effects, both acute and delayed:If swallowed, DO NOT induce vomiting. May cause allergy or asthma symptoms or breat ties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonge exposure. Excessive exposure may aggravate preexisting other respiratory disorders (e.g. emphysema, b tive airways dysfunction syndrome). Contact with dust can cause mechanical irritatio the skin.Protection of first-aiders:First Aid responders should pay attention to sel and use the recommended personal protective	FIGHTING MEASURES		
If inhaledif inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.In case of skin contactin case of contact, immediately flush skin with s of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. Thoroughly clean shoes before reuse.In case of eye contactin case of contact, immediately flush eyes with for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.If swallowedif swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.Most important symptoms and effects, both acute and delayedif swallowed, DO NOT induce vomiting. May cause allergy or asthma symptoms or breat ties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonge exposure. Excessive exposure may aggravate preexisting other respiratory disorders (e.g. emphysema, b tive airways dysfunction syndrome). Contact with dust can cause mechanical irritatio the skin.Protection of first-aidersif site as the recommended personal protective	otes to physician	:	
If inhaledIf inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.In case of skin contactIn case of contact, immediately flush skin with s of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. In case of eye contactIn case of eye contactIn case of contact, immediately flush eyes with for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.If swallowedIf swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.Most important symptoms and effects, both acute and delayedIf swallegy or asthma symptoms or breat ties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonge exposure. Excessive exposure may aggravate preexisting other respiratory disorders (e.g. emphysema, b tive airways dysfunction syndrome). Contact with dust can cause mechanical irritation	otection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled:If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.In case of skin contact:In case of contact, immediately flush skin with so of water. Remove contaminated clothing and shoes. Get medical attention. 			May cause damage to organs through prolonged or repeated exposure. Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac- tive airways dysfunction syndrome). Contact with dust can cause mechanical irritation or drying of
If inhaled:If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.In case of skin contact:In case of contact, immediately flush skin with s of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.In case of eye contact:In case of contact, immediately flush eyes with for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.If swallowed:If swallowed, DO NOT induce vomiting.	d effects, both acute and	:	Rinse mouth thoroughly with water. Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficul- ties if inhaled.
If inhaled:If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.In case of skin contact:In case of contact, immediately flush skin with s of water. Remove contaminated clothing and shoes. Get medical attention.In case of eye contact:In case of contact, immediately flush skin with s of water. Remove contaminated clothing and shoes. Get medical attention. 	swallowed	:	If easy to do, remove contact lens, if worn. Get medical attention. If swallowed, DO NOT induce vomiting.
If inhaledadvice.If inhaled:If inhaled, remove to fresh air.If not breathing, give artificial respiration.If breathing is difficult, give oxygen.Get medical attention.In case of skin contact:In case of skin contact:	case of eye contact	:	Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. In case of contact, immediately flush eyes with plenty of water
advice. If inhaled : If inhaled, remove to fresh air.	case of skin contact	:	If breathing is difficult, give oxygen. Get medical attention. In case of contact, immediately flush skin with soap and plenty
vice immediately.		:	When symptoms persist or in all cases of doubt seek medical advice. If inhaled, remove to fresh air.

Suitable extinguishing media :

Water spray Alcohol-resistant foam Carbon dioxide (CO2)

according to the Globally Harmonized System



### Imipenem / Cilastatin / Relebactam Formulation

Vers 6.0	sion	Revision Date: 28.09.2024		9S Number: 823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015	
				Dry chemical		
	Unsuitable extinguishing media		:	None known.		
	Specific hazards during fire- fighting		:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.		
	Hazard ucts	ous combustion prod-	:	Carbon oxides Metal oxides		
	Specific extinguishing meth- ods		:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do	
	Special for firef	protective equipment ighters	:		e, wear self-contained breathing apparatus. ective equipment.	

#### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfac- es, as these may form an explosive mixture if they are re- leased into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding

according to the Globally Harmonized System



### Imipenem / Cilastatin / Relebactam Formulation

Version 6.0	Revision Date: 28.09.2024	SDS Number: 68823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015	
		certain local	or national requirements.	
7. HANDL	ING AND STORAGE			
	nical measures	causing an e Provide adec and bonding,	uate precautions, such as electrical grounding or inert atmospheres.	
Local/Total ventilation Advice on safe handling		: Do not breath Do not swalld Do not get in Avoid prolong Wash skin th Handle in acc practice, bas sessment Keep contain Already sens to asthma, al should consu- tory irritants of Minimize dus Keep contain Keep away fr Take precaut	ow. eyes. ged or repeated contact with skin. oroughly after handling. cordance with good industrial hygiene and safety ed on the results of the workplace exposure as- er tightly closed. itised individuals, and those susceptible lergies, chronic or recurrent respiratory disease, lt their physician regarding working with respira- or sensitisers. t generation and accumulation. er closed when not in use. om heat and sources of ignition. ionary measures against static discharges. prevent spills, waste and minimize release to the	
	litions for safe storage rials to avoid	Store locked up. Keep tightly closed. Store in accordance with the particular national regulations		

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Cilastatin	81129-83-1	TWA	5 mg/m3 (OEB 1)	Internal
Imipenem	74431-23-5	TWA	3000 ug/m3 (OEB	Internal
			1)	
	Further informa	ation: RSEN, DS	SEN	
		Wipe limit	100 µg/100 cm2	Internal
Relebactam	1174020-13-	TWA	0.3 mg/m3 (OEB	Internal
	3		2)	

according to the Globally Harmonized System



### Imipenem / Cilastatin / Relebactam Formulation

Version 6.0	Revision Date: 28.09.2024	SDS N 68823-	umber: 00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015
Eng	ineering measures	cor All des	npound. engineerin sign and op	engineering controls to minimize exposure to og controls should be implemented by facility berated in accordance with GMP principles to cts, workers, and the environment.
Pers	onal protective equip	ment		
·	piratory protection	sur om	e assessm	ncal exhaust ventilation is not available or expo- nent demonstrates exposures outside the rec- uidelines, use respiratory protection.
	d protection	. 14	tioulates tj	,pc
Ν	laterial	: Ch	emical-resi	istant gloves
Eye	Eye protection		Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.	
Skin	and body protection			or laboratory coat.
Hygi	Hygiene measures		shing syste ce. len using d lsh contam e effective gineering c propriate d ustrial hygi	chemical is likely during typical use, provide eye oms and safety showers close to the working lo not eat, drink or smoke. inated clothing before re-use. operation of a facility should include review of ontrols, proper personal protective equipment, egowning and decontamination procedures, iene monitoring, medical surveillance and the strative controls.

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	White to light yellow
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable

according to the Globally Harmonized System



# Imipenem / Cilastatin / Relebactam Formulation

Versi 6.0	on	Revision Date: 28.09.2024		S Number: 23-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015
r	Flamm	ability (solid, gas)		May form avalage	ive dust-air mixture during processing, han-
Г	FIdIIIII	adility (Solid, gas)	•	dling or other me	81 8 <sup>1</sup>
F	Flamma	ability (liquids)	:	Not applicable	
		explosion limit / Upper bility limit	:	No data available	9
		explosion limit / Lower bility limit	:	No data available	9
١	Vapour	pressure	:	Not applicable	
F	Relative	e vapour density	:	Not applicable	
F	Relative	e density	:	No data available	9
[	Density	,	:	No data available	9
S	Solubili Wat	ty(ies) er solubility	:	soluble	
	Partitio	n coefficient: n-	:	Not applicable	
		nition temperature	:	No data available	9
[	Decom	position temperature	:	No data available	9
١	Viscosi Visc	ty cosity, dynamic	:	No data available	9
	Visc	osity, kinematic	:	Not applicable	
E	Explosi	ve properties	:	Not explosive	
(	Oxidizir	ng properties	:	The substance o	r mixture is not classified as oxidizing.
ľ	Molecu	lar weight	:	No data available	9
	Particle Particle	e characteristics e size	:	No data available	9

### **10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	May form explosive dust-air mixture during processing, han-
tions		dling or other means.
		Can react with strong oxidizing agents.



according to the Globally Harmonized System

ersion D	Revision Date: 28.09.2024		S Number: 823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015	
Conditions to avoid Incompatible materials Hazardous decomposition products		<ul> <li>Heat, flames and sparks. Avoid dust formation.</li> <li>Oxidizing agents</li> <li>No hazardous decomposition products are known.</li> </ul>			
. TOXIC	OLOGICAL INFORMA	TION	1		
Information on likely routes of exposure		:	Inhalation Skin contact Ingestion Eye contact		
	e <b>toxicity</b> assified based on availa	able	information.		
Comp	oonents:				
Cilast	atin:				
Acute	oral toxicity	:	LD50 (Rat): 8,0	00 mg/kg	
			LD50 (Mouse):	8,000 mg/kg	
Imipe					
Acute	oral toxicity	:	LD50 (Mouse):	10,000 mg/kg	
	toxicity (other routes of istration)	:	LD50 (Rat): > 2 Application Rou		
			LD50 (Mouse): Application Rou		
Skin o	corrosion/irritation				
	assified based on availa	able	information.		
Comp	oonents:				
Cilast	atin:				
Speci Resul		:	Rabbit No skin irritatior		
Invesu	ı	•	INO SAILI ILLIAUUI	1	
	actam:				
Metho Resul	od t	:	EpiDerm No skin irritatior		
••	՝ us eye damage/eye irr	itati			
	es serious eye irritation.				
Comp	oonents:				
	oonents:				

according to the Globally Harmonized System



ersion .0	Revision Date: 28.09.2024		DS Number: 823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015			
Spec Resu		:	Rabbit Moderate eye i	rritation			
Relet	pactam:						
Method Result			Bovine cornea (BCOP) No eye irritation				
Resp	iratory or skin sens	itisatio	on				
	sensitisation lassified based on av	ailable	information.				
-	iratory sensitisation						
		na syn	ptoms or breath	ing difficulties if inhaled.			
<u>Com</u>	ponents:						
Cilas							
Expo Rema	sure routes arks	:	Skin contact No data availat	ble			
Expo Rema	sure routes arks	:	Inhalation No data availat	ble			
	enem:						
Rema	arks	:	May cause sen of aerosol or du	sitisation of susceptible persons by inhalatior ust.			
Expo Rema	sure routes arks	:	Skin contact Not classified c	lue to lack of data.			
	pactam:						
Test Expo Resu	sure routes	:	Local lymph no Dermal Not a skin sens	de assay (LLNA) sitizer.			
	n cell mutagenicity	-:	in farma stires				
	lassified based on av ponents:	allable	information.				
	tatin:						
	toxicity in vitro	:	Test Type: Mic Result: negativ	robial mutagenesis assay (Ames test) e			
Imipe	enem:						
	toxicity in vitro	:		itro mammalian cell gene mutation test hinese hamster lung cells e			
			9/20				

according to the Globally Harmonized System



Version 6.0	Revision Date: 28.09.2024	SDS Numl 68823-000	
			ype: reverse mutation assay : negative
			ype: unscheduled DNA synthesis assay : negative
			ype: Chromosomal aberration : negative
			ype: sister chromatid exchange assay : negative
Geno	otoxicity in vivo	Specie	ype: In vivo micronucleus test es: Mouse
			ation Route: Intravenous : negative
II Relel	bactam:		
Genc	otoxicity in vitro		ype: Bacterial reverse mutation assay (AMES) : negative
			ype: Chromosome aberration test in vitro
Geno	otoxicity in vivo		ype: Mutagenicity (in vivo mammalian bone-marrow enetic test, chromosomal analysis) es: Rat
		Applica	ation Route: Intraperitoneal injection : negative
	n cell mutagenicity - ssment		t of evidence does not support classification as a germ utagen.
II Carc	inogenicity		
Not c	lassified based on ava	ilable informa	ition.
-	oductive toxicity		
	ected of damaging the ponents:	undorn child.	
	tatin: ts on fertility	Applica	ype: Fertility/early embryonic development ation Route: Intravenous y: LOAEL: 1,000
		Sympt Result	oms: No adverse effects : No effects on fertility and early embryonic develop- vere detected.
II Imine	enem:		
	ts on fertility	: Test T	ype: Fertility/early embryonic development
			10/20

according to the Globally Harmonized System



ersion .0	Revision Date: 28.09.2024	SDS Number: 68823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015
		Application R Fertility: LOA Symptoms: N	, male and female coute: Intravenous EL: 80 mg/kg body weight lo adverse effects, Reduced foetal weight fects on fertility and early embryonic develop- etected.
		Species: Rat Application R Fertility: LOA Symptoms: N	ertility/early embryonic development , male and female oute: Subcutaneous EL: 320 mg/kg body weight lo adverse effects, Reduced foetal weight fects on fertility and early embryonic develop- etected.
Effect ment	s on foetal develop-	Development Result: Embr	
		Development	
		Development	evelopment oute: Intravenous al Toxicity: NOAEL: 60 mg/kg body weight ratogenic effects
Repro sessn	oductive toxicity - As- nent	: Some eviden animal exper	ce of adverse effects on development, based on iments.
Relet	bactam:		
	s on fertility	Species: Rat Application R	re-/postnatal development coute: Subcutaneous .EL: 450 mg/kg body weight
Effect ment	s on foetal develop-	Species: Rat Application R Embryo-foeta	mbryo-foetal development coute: Intraperitoneal injection al toxicity: NOAEL: 450 mg/kg body weight fects on foetal development
		Species: Mou	mbryo-foetal development use coute: Intraperitoneal injection

according to the Globally Harmonized System



tion			
Version 6.0	Revision Date: 28.09.2024	SDS Number: 68823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015
			al toxicity: NOAEL: 450 mg/kg body weight ffects on foetal development
		Developmen	t Route: Intravenous Ital Toxicity: NOAEL: >= 450 mg/kg body weight ffects on fertility and early embryonic develop-
		Developmen	
	<b>Γ - single exposure</b> lassified based on ava	ilable information.	
	<b>Γ - repeated exposure</b> cause damage to orga		prolonged or repeated exposure.
Com	ponents:		
Rele	pactam:		
-	et Organs ssment	: Kidney : May cause of exposure.	lamage to organs through prolonged or repeated
Repe	ated dose toxicity		
-	ponents:		
Cilas	tatin:		
	EL cation Route sure time	: Rat : >= 500 mg/k : Intravenous : 90 Days : No significar	g nt adverse effects were reported
	EL cation Route sure time	: Monkey : >= 500 mg/k : Intravenous : 5 Weeks : No significar	g nt adverse effects were reported
Imipe	enem:		
Spec NOAI LOAE Appli	ies EL	: Monkey : 60 mg/kg : 150 mg/kg : Intravenous : 6 Months	

according to the Globally Harmonized System



# Imipenem / Cilastatin / Relebactam Formulation

Version 6.0	Revision Date: 28.09.2024		DS Number: 823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015
Targe	et Organs	:	Kidney	
	EL cation Route sure time		Monkey 120 mg/kg Subcutaneous 6 Months No significant	adverse effects were reported
Spec NOA Appli Expo Rema	EL cation Route sure time		Rat 180 mg/kg Intravenous 6 Months No significant	adverse effects were reported
Spec LOAE Appli Targe			Rabbit 150 mg/kg Intravenous Kidney	
Spec NOA Appli		:	Rat, female 150 mg/kg Intravenous 30 d	
		:	Rat, male 450 mg/kg Intravenous 30 d	
Expo		:	Monkey 25 mg/kg Intravenous 30 d Kidney	
	ies EL cation Route sure time	:	Monkey 37.5 mg/kg Intravenous 30 d	
Expo	EL		Monkey 50 mg/kg 150 mg/kg Intravenous 3 Months Kidney	

#### Aspiration toxicity

Not classified based on available information.

according to the Globally Harmonized System



# Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	28.09.2024	68823-00030	Date of first issue: 27.02.2015

#### Experience with human exposure

#### Components:

#### Imipenem:

impenem:	
Inhalation	: Symptoms: Nausea, Vomiting, Diarrhoea, Fever, hypotension, Dizziness, Drowsiness, Convulsions, pruritis, Rash Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust.
Relebactam:	
Skin contact	: Symptoms: Pain, Discomfort, Diarrhoea, Abdominal pain, insomnia, Nausea, sore throat, Vertigo

#### 12. ECOLOGICAL INFORMATION

#### Components:

### Cilastatin:

Cilastatin:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 99 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 ( Anabaena flos-aquae): > 99 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		EC50 ( Pseudokirchneriella subcapitata (green algae)): > 99 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC ( Anabaena flos-aquae): 99 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC ( Pseudokirchneriella subcapitata (green algae)): 99 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic tox-	:	EC10: > 9.9 mg/l

according to the Globally Harmonized System



rsion )	Revision Date: 28.09.2024		9S Number: 823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015
icity) Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)			Exposure time: 32 Species: Pimepha Method: OECD To	ales promelas (fathead minnow)
		:	Exposure time: 21	magna (Water flea)
Imipe	enem:			
Toxici		:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
Toxici plants	ity to algae/aquatic	:	EC50 ( Anabaena Exposure time: 72 Method: OECD Te	
			NOEC (Anabaen Exposure time: 72 Method: OECD Te	
			EC50 ( Pseudokir mg/l Exposure time: 72 Method: OECD Te	
			NOEC ( Pseudoki mg/l Exposure time: 72 Method: OECD Te	
M-Fac icity)	ctor (Acute aquatic tox-	:	100	
Toxici	ity to microorganisms	:	EC50: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
Toxici icity)	ity to fish (Chronic tox-	:	NOEC: 9.4 mg/l Exposure time: 32 Species: Pimepha Method: OECD Te	ales promelas (fathead minnow)
	ity to daphnia and other ic invertebrates (Chron- icity)	:	NOEC: 11 mg/l Exposure time: 21 Species: Daphnia Method: OECD Te	magna (Water flea)
M-Fac toxicit	ctor (Chronic aquatic y)	:	10	

according to the Globally Harmonized System



# Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	28.09.2024	68823-00030	Date of first issue: 27.02.2015

# 

••		
Relebactam:		
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
		EC50 (Americamysis): > 100 mg/l Exposure time: 96 h
Toxicity to algae/aquatic plants	:	EC50 ( Pseudokirchneriella subcapitata (green algae)): 86 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 12 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		EC50 ( Anabaena flos-aquae (cyanobacterium)): > 11 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC ( Anabaena flos-aquae (cyanobacterium)): 11 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC: 96.3 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic tox- icity)	:	NOEC: 9.2 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)	:	NOEC: 2.7 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

#### Persistence and degradability

#### Components:

#### Cilastatin:

according to the Globally Harmonized System



Version 6.0	Revision Date: 28.09.2024		DS Number: 823-00030	Date of last issue: 30.09.2023 Date of first issue: 27.02.2015
Biode	egradability	:	Result: Not readily Biodegradation: 2 Exposure time: 28 Method: OECD To	27 %
Imip	enem:			
	egradability	:	Result: Not readily Biodegradation: 2 Exposure time: 28 Method: OECD Te	29 %
Rele	bactam:			
	egradability	:	Result: Not readily Biodegradation: Exposure time: 28 Method: OECD To	11.3 % 3 d
Bioa	ccumulative potential			
<u>Com</u>	ponents:			
Cilas	statin:			
	tion coefficient: n- nol/water	:	log Pow: -3.53	
Imipo	enem:			
	tion coefficient: n- nol/water	:	log Pow: < -1	
Rele	bactam:			
Partit octar	tion coefficient: n- nol/water	:	log Pow: < -2	
Mobi	ility in soil			
Com	ponents:			
Cilas	statin:			
Distri	bution among environ- al compartments	:	log Koc: 2.3	
Rele	bactam:			
	bution among environ- al compartments	:	log Koc: 2.3	
	<b>r adverse effects</b> ata available			

according to the Globally Harmonized System



### Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	28.09.2024	68823-00030	Date of first issue: 27.02.2015

#### 13. DISPOSAL CONSIDERATIONS

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

#### 14. TRANSPORT INFORMATION

#### **International Regulations**

UNRTDG		
UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes
IATA-DGR		
UN/ID No.	:	UN 3077
Proper shipping name	:	Environmentally hazardous substance, solid, n.o.s. (Imipenem)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	956
Packing instruction (passen- ger aircraft)	:	956
Environmentally hazardous	:	yes
IMDG-Code		
UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
		(Imipenem)
Class	:	9
Packing group	:	
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

#### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data



### Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	28.09.2024	68823-00030	Date of first issue: 27.02.2015

Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

#### **16. OTHER INFORMATION**

Revision Date	:	28.09.2024
Further information Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-



### Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	28.09.2024	68823-00030	Date of first issue: 27.02.2015

ment; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN